MCL

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Timothy Long, M.D., about the importance of asking good questions in healthcare settings, such as with patients, as an educator, and in conference or presentation settings.

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many kinds of cancer.

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Reade Quinton, M.D., an associate professor of laboratory medicine and pathology and anatomic pathologist at Mayo Clinic to discuss interview tips for future pathology residents.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich,[...]

PACE / State of FL - This webinar will delve into the latest ASCO guidelines for selection of germline genetic testing panels for cancer patients. Key topics include the importance of taking and recording a detailed family and personal history, selecting the appropriate genes for testing, and determining when and to whom germline testing should be offered. The session will also address the practical implications of the ASCO guidelines, such as balancing the potential benefits of broader gene panel testing with the risks associated with uncertain results. Additionally, participants will gain insights into the specific technical challenges associated with germline genetic testing in cancer care and risk management.